MOTS-c
A 16-amino-acid mitochondrial-encoded peptide studied for metabolic homeostasis, insulin sensitivity, and exercise-mimetic biology.
What MOTS-c is
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. Discovered and characterized in work led by Cohen and colleagues, it functions as a signaling molecule that links mitochondrial status to cellular and systemic metabolic responses. Preclinical research is the backbone of the MOTS-c story. Mouse studies reported that MOTS-c promoted metabolic homeostasis and reduced diet- and age-associated insulin resistance phenotypes, with skeletal muscle emerging as an important target tissue. Later work described nuclear translocation under metabolic stress and regulation of nuclear gene expression, expanding the peptide beyond a purely cytosolic messenger. Human biology papers continue to map circulating levels and metabolite correlates. For educational dosage pages, distinguish animal mg/kg experiments from informal human research-protocol milligram schedules circulating online. MOTS-c is discussed here strictly as a research compound and literature subject. Ranges below summarize what secondary research communities commonly cite and what primary papers established mechanistically, not a directive to administer the peptide.
Nearly all of the published work on MOTS-c is preclinical: animal models and cell studies. Human evidence is thinner than the volume of online discussion suggests.
How it works
MOTS-c is reported to influence one-carbon metabolism (folate/methionine cycle) and to activate AMPK-related energy-sensing pathways, especially in skeletal muscle contexts. Under metabolic stress it can traffic to the nucleus and adjust expression of genes involved in cellular metabolism and stress adaptation. Downstream readouts in models include improved glucose utilization, shifts in plasma metabolites, and resistance to high-fat-diet metabolic strain. The peptide is therefore framed as a mitokine-like messenger rather than a classical cell-surface hormone only.
Where this compound shows up in research
Mitochondrial biologists, endocrinology labs focused on insulin resistance, and geroscience groups tracking mitokines. Exercise physiologists examine MOTS-c as a candidate exercise-responsive signal. Clinical interest exists but large therapeutic registration programs are not the same as the early discovery literature.
What the research examines
These are areas of active investigation. Listing a topic here does not mean an effect is established, approved, or proven in humans.
How it appears in the literature
What the published work actually used. Reference only, not instructions.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Commonly cited secondary research-protocol ranges for subcutaneous investigation (not a standardized approved dose) | 5 mg – 10 mg | 2-3 times weekly (as often described in secondary protocols) | subcutaneous |
| Preclinical metabolic studies (order-of-magnitude reference only) | Not a fixed mcg value | study-defined | injection (species-specific) |
Handling & storage
Store lyophilized MOTS-c refrigerated or frozen per supplier COA, away from moisture and light. After reconstitution with bacteriostatic water, keep refrigerated and aliquot if freeze-thaw is a concern; observe labeled beyond-use dating.
Notes on combined research
Metabolic research sometimes discusses MOTS-c conceptually alongside other mitochondrial peptides (for example humanin family members) or alongside exercise interventions. Combining with incretin agonists is an uncontrolled idea online, not a validated co-protocol. Mechanistic clarity favors studying MOTS-c with defined diet/exercise covariates rather than large peptide stacks.
MOTS-c questions
No FDA-approved human dose exists for general use. Secondary research-protocol sources often mention multi-milligram subcutaneous amounts several times per week (commonly discussed near 5-10 mg weekly total). Primary literature dose tables are mostly animal mg/kg. Treat blog numbers as unverified unless tied to a methods section.
For a 10 mg vial, 1-2 mL bacteriostatic water yields 10 or 5 mg/mL, which keeps weekly research aliquots easy to measure. For a 40 mg vial, 2-3 mL is a frequent choice. Always recompute units after measuring the actual diluent added.
Many informal protocols prefer several weekly injections rather than true daily microdosing. If a source lists a daily figure, convert it to weekly exposure and compare against the commonly cited 5-10 mg/week band, then verify against any primary human study you are following.
Chart concentration versus syringe units. Example: 10 mg in 2 mL = 5 mg/mL; 0.2 mL = 1 mg; 1.0 mL = 5 mg. Separate rows for twice-weekly versus three-times-weekly schedules help avoid double-counting weekly totals.
Mouse metabolic endpoints are often measured over days to weeks of dosing. Human exploratory work and analog programs use study-specific durations. There is no single validated results timeline for educational marketing claims.
Native mitochondrial peptides are generally not ultra-long-acting biologics. Use primary pharmacokinetic reports when available; do not assume weekly exposure equals a one-week biological half-life.
Research designs may combine MOTS-c with exercise, diet challenges, or other metabolic readouts. Stacking multiple uncharacterized research peptides simultaneously weakens causal inference. Prefer controlled single-variable studies.
Read the research yourself
Every link below was verified against the NCBI PubMed database. We do not cite what we cannot point you to.
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.PubMed
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.PubMed
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.PubMed
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.PubMed